Core Viewpoint - Nxera Pharma is undergoing a focused restructuring to concentrate investments on high-value programs and reduce operating expenses, aiming for net sales of ≥JPY50 billion and an operating profit margin of ≥30% by 2030 [1][5] Restructuring Objectives - The restructuring aims to prioritize high-probability, high-return programs and streamline operations to enhance efficiency and accelerate program progression [5][6] - A portfolio review has identified non-priority programs for potential partnership or termination, focusing on next-generation therapies for obesity and metabolic disorders [6][12] Financial Strategy - Nxera plans to reduce cash R&D expenditure by approximately JPY3.5 billion in FY2026 and expects a minimum of JPY1.0 billion in year-on-year savings [6][11] - The company maintains a strong cash position with current cash and liquid investments of JPY30.9 billion, allowing flexibility in executing its strategy [6][11] Leadership Changes - Dr. Patrick Foerch has been appointed as Chief Scientific Officer and President of Nxera Pharma UK, bringing significant experience to enhance R&D focus [5][9] - The executive team will be reduced from ten to seven members by March 2026, and a workforce reduction of approximately 15% will occur across Japan and UK operations [6][11] R&D Focus - Nxera will leverage its NxWave™ platform, utilizing AI technology to enhance drug discovery and development, particularly in GPCR-targeted programs [6][12] - The company has an extensive pipeline of over 30 active programs, with several partnered programs progressing through clinical development [12]

Core Viewpoint - Nxera Pharma Co., Ltd. is undergoing a focused restructuring to concentrate investments on high-value programs and reduce operating expenses, aiming for net sales of ≥JPY50 billion and an operating profit margin of ≥30% by 2030 [1][5] Restructuring Objectives - The restructuring aims to prioritize higher-probability, high-return programs and streamline operations to enhance efficiency and accelerate momentum in clinically and commercially viable programs [5][6] - Nxera plans to reduce cash R&D expenditure by approximately JPY3.5 billion in FY2026 and implement a workforce reduction of about 15% across Japan and UK operations [6][11] R&D Focus and Program Prioritization - The strategic emphasis will be on next-generation therapies for obesity, metabolic, and endocrine disorders, leveraging the NxWave™ platform for differentiated medicines [6][13] - AI technology will be integrated into the NxWave™ platform to enhance drug discovery and decision-making processes [6][7] Leadership Changes - Dr. Patrik Foerch has been appointed as Chief Scientific Officer and President of Nxera Pharma UK, bringing extensive experience in R&D leadership [10][11] - The executive team will be streamlined from ten to seven members by March 2026 [6][11] Financial Position and Cost Management - Nxera maintains a strong cash position with current cash and liquid investments of JPY30.9 billion, allowing flexibility in executing its strategy [6][11] - One-time restructuring charges of approximately JPY500 million will be recognized in FY2025, with expected cost savings of at least JPY1.0 billion in the following year [6][11]